ARACHITOL 3L INJ

The Arachitol 3L IU Injection by Abbott India Ltd is a high-potency, intramuscular injectable formulation of Cholecalciferol (Vitamin D3) delivering 300,000 IU per ampoule, specifically indicated for the treatment and correction of clinically significant Vitamin D deficiency in dogs, cats, cattle, horses, pigs, and other companion or farm animals. Vitamin D deficiency is a widespread and frequently underdiagnosed condition in pets and livestock that undermines skeletal integrity, impairs calcium and phosphate metabolism, compromises immune function, and contributes to debilitating musculoskeletal disorders including rickets, osteomalacia, and hypocalcaemia. The Arachitol 3L IU Injection targets this deficiency at its root, delivering a therapeutic bolus of Cholecalciferol that rapidly restores serum Vitamin D3 levels and initiates the cascade of physiological processes necessary for proper bone mineralisation and calcium homeostasis. Manufactured by Abbott India Ltd, a global leader in pharmaceutical science with a presence in over 160 countries, this injectable formulation meets the exacting standards of safety, sterility, and bioavailability expected of a trusted clinical pharmaceutical product. Offer the Arachitol 3L IU Injection as part of its veterinary pharmaceutical range for pet parents and animal care professionals who demand precision-grade nutritional therapy for their animals.

Ingredients:

Cholecalciferol (Vitamin D3), 300,000 IU (equivalent to 7.5 mg) per ampoule:

Cholecalciferol (Vitamin D3) is a fat-soluble secosteroid prohormone synthesised naturally in the skin upon exposure to ultraviolet-B radiation and obtained additionally from dietary sources. At the molecular level, Cholecalciferol undergoes a two-step hydroxylation process following administration. The first hydroxylation occurs in the hepatic parenchymal cells, converting Cholecalciferol to 25-hydroxyvitamin D3 (calcidiol), the primary circulating storage form of Vitamin D. The second and biologically decisive hydroxylation occurs in the proximal tubular cells of the kidneys, producing 1,25-dihydroxyvitamin D3 (calcitriol), the hormonally active metabolite. Calcitriol binds to the nuclear Vitamin D receptor (VDR) found in intestinal epithelial cells, osteoblasts, renal tubular cells, and immune cells, initiating transcriptional activity that upregulates the expression of calcium-binding proteins such as calbindin-D9k. This mechanism directly enhances the intestinal absorption of calcium and inorganic phosphate from the gut, increases renal tubular reabsorption of calcium, and regulates the activity of osteoblasts and osteoclasts to facilitate the deposition of calcium into the bone matrix. The end result is a measurable, dose-dependent increase in serum calcium and phosphate concentrations, restoration of appropriate bone mineralisation density, and correction of the skeletal deformities and metabolic disturbances associated with Vitamin D insufficiency.